Contact
Please use this form to send email to PR contact of this press release:
ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR CAPLACIZUMAB, ITS ANTI-vWF NANOBODY, FOR THE TREATMENT OF aTTP
TO: